Viridian’s Elegrobart Data: Promising Proptosis Win, But Missing the Full Picture for Thyroid Eye Disease

Viridian highlights 54% proptosis response for Elegrobart in TED, but secondary endpoints like inflammation and diplopia showed limited gains.